Previous 10 | Next 10 |
Cranbury, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publication on preclinical data...
Rafael Holdings press release (NYSE:RFL): Q3 GAAP EPS of -$0.28. Revenue of $0.88M (-11.1% Y/Y). As of April 30, 2022, we had cash, cash equivalents and marketable securities of $59.4 million. For further details see: Rafael Holdings GAAP EPS of -$0.28, revenue of $0.88M
NEWARK, N.J., June 14, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics company, today reported its financial results for the three and nine months ended April 30, 2022. The Company is focused on accelerating the deve...
In its 34th annual Russell indexes annual reconstitution, following financials/real estates stocks will be added to and deleted from the Russell 3000 Index. While UnitedHealth and Nvidia replaced financial companies JPMorgan Chase and Visa in top 10 largest companies by market cap in Ru...
Cranbury, NJ, June 01, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that the Company and its partne...
The European Medicines Agency (EMA) granted orphan drug designation to Cornerstone Pharmaceuticals' CPI-613 (devimistat) to treat advanced unresectable biliary tract cancer. Earlier in May, Rafael Pharmaceuticals, a part of Rafael Holdings (NYSE:RFL), had changed its name ...
Cranbury, NJ, May 24, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that the European Medicines Agency (...
Rafael Pharmaceuticals (NYSE:RFL) announced that it is changing its name to Cornerstone Pharmaceuticals, its original company name. New trials in the pipeline for hematologic and solid tumors will launch in Q2 and Q3 2022. The company's clinical trials in Burkitt's lymphoma, b...
Cranbury, NJ, May 19, 2022 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the development of rare cancer therapeutics, today announced that it is changing its name to Cornerstone Pharmaceuticals, Inc. ( ...
Kahn Brothers’ 13F portfolio value increased from $741M to $788M this quarter. Citigroup, ViewRay, and VOXX International were increased during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~48% of the 13F holdings. ...
News, Short Squeeze, Breakout and More Instantly...
Rafael Holdings Inc. Class B Company Name:
RFL Stock Symbol:
NYSE Market:
Rafael Holdings Inc. Class B Website:
NEWARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today announced that its Board of Directors has authorized the repurchase of up to $5 million of the Company's Class B common stock. “We remain committed to strategically and opportunistically deployi...
NEWARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its second quarter fiscal 2023 financial results for the three months and six months ended January 31, 2023. “Our strong balance sheet allows us to continue to fund our pipeline assets ...
NEWARK, N.J., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its first quarter fiscal 2023 financial results for the three months ended October 31, 2022. “We are pleased to have successfully completed the sale of our real estate asset located in N...